APOGEE THERAPEUTICS INC (APGE)
Health Care · biotechnology · NASDAQ
Apogee Therapeutics is a clinical-stage biotechnology firm developing advanced biologic therapies for inflammatory and immunology diseases, currently pending acquisition by AbbVie.
What APOGEE THERAPEUTICS INC does
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologic product candidates for the treatment of inflammatory and immunology conditions. Its development programs target high unmet needs in diseases including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. The company is currently a party to a pending acquisition agreement with AbbVie.
Themes: immunology, inflammatory diseases, biologics, mergers and acquisitions
Fundamentals
- Price$134.75 as of 2026-08-21 close
- Market cap$10.2B as of 2026-08-24
- 1-year return+270.7% 2025-08-21 close $36.35 → 2026-08-21 close $134.75
- P/En/a earnings data not available
- ROE-32.6% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.22 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How APGE compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
APGE is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no growth data.
Short-term score
48.1 #914 of 1,704 scored · #161 of 240 in Health Care
Trend 74th: a strong uptrend, with buyers in control; volume and participation 72nd: it gapped 46.7% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is momentum 35th: MACD momentum is negative. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How APOGEE THERAPEUTICS INC looks technically
APOGEE THERAPEUTICS INC (APGE) is trading 52.8% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 210 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 62, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70). It made a new 20-day high about 11 trading days ago. It is trading at or near its all-time high. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 10% of the past ~6 months), which often precedes a bigger move.
Trend
7
| Distance from the 200-day | it is trading 52.8% above its 200-day average, the long-term trend line — a longer-term uptrend | +52.8% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $128.40 | $128.40 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $88.17 | $88.17 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 210 trading days ago — a "golden cross", a bullish long-term signal | 210 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 62, with buyers in control | 62.3 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 78, in overbought territory (above 70) | 77.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($134.06 to $134.88) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. Read that with care: its whole 14-day range is only about 0.6% of the price, so being at one end of it is a smaller move than it sounds — a company pinned near an agreed takeover price does this. | 84.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 31 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $134.88 | $134.88 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.1% |
| Above the 52-week low | it is 280.8% above its 52-week low (its lowest price of the past year) | +280.8% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.1% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $134.88 (set on 2026-08-07) | $134.88 |
| Given back of the 52-week move | over the past year its closes ranged ($36.02 to $134.84), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $70.61 to $73.77. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.1% |
| From the all-time high | it is trading at or near its all-time high | -0.1% |
| Nearest price level | it is sitting right on a support level at $134.13 — a price it turned at four times since 2026-06-23, most recently on 2026-08-07. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $14.19 (set on 2023-11-10) | $14.19 |
| Above the all-time low | it is 849.6% above its all-time low | +849.6% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 10% of the past ~6 months), which often precedes a bigger move | 10th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.5196 between its high and its low — about 0.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.5196 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $133.99 and $134.93 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $133.99 – $134.46 – $134.93 |
| Typical daily range (% of price) | its price moves about 0.4% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 0.4% |
| Stretch from the 200-day average | it is trading 89.7 daily ranges above its 200-day average price (52.8% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale. Read that multiple with care: this company's daily range is unusually small (about 0.4% of its price), which is what makes the multiple large — a stock trading in a narrow band near a takeover price does this | 89.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.80× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 3.3% since the prior reading | +3.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.27 toward sell |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.0% |
|---|---|---|
| Open gap | it gapped 46.7% above the previous close 43 sessions ago and has not traded back through the level it left behind at 90.38 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +46.7% |
| Gap filled | a 2.9% gap up opened on 2026-06-18 has been "filled" 44 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 44 sessions ago |
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.9 percentage points (the stock gained 0.4% while the market gained 2.3%) | -1.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 60.4 percentage points (the stock gained 63.5% while the market gained 3.1%) | +60.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 86.0 percentage points (the stock gained 97.0% while the market gained 11.1%) | +86.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 250.2 percentage points (the stock gained 270.7% while the market gained 20.5%) | +250.2% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 12.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +11.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 23% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $109.68 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +22.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $134.62 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +0.1% |
Price levels it has turned at before
APGE last closed at $134.75 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $134.13 | Support | 0.5% below the last close | turned there four times · 2026-06-23 to 2026-08-07 |
| $80.75 | Support | 40.1% below the last close | turned there twice · 2025-12-19 to 2026-05-04 |
| $73.06 | Support | 45.8% below the last close | turned there twice · 2025-12-17 to 2026-01-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · Analyst price target recently RAISED | Learn: moving average · golden cross · adx · rsi · breakout · all time high · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.87 mean, 1=Strong Buy…5=Strong Sell) — 11 analysts
- Mean price target$134.85 range $133.00 – $135.11; median $135.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for APGE
- Consensus EPS estimate-$0.9611 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Failure to complete the pending merger with AbbVie due to regulatory or closing conditions.","Risks associated with the clinical-stage nature of product candidates and the uncertainty of regulatory approval.","High dependence on third parties for clinical trial conduct and drug manufacturing."]
What changed in the latest 10-Q
AI-assisted comparison of APGE's 10-Q filed 2026-05-11 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Page number for Item 2 (MD&A) changed from 25 to 24 in newer filing (2026-05-11)
- Page number for Item 3 (Quantitative and Qualitative Disclosures About Market Risk) changed from 43 to 37 in newer filing (2026-05-11)
- Page number for Item 4 (Controls and Procedures) changed from 43 to 37 in newer filing (2026-05-11)
- Page number for PART II OTHER INFORMATION changed from 44 to 38 in newer filing (2026-05-11)
- Page number for Item 1 (Legal Proceedings) changed from 44 to 38 in newer filing (2026-05-11)
- Notes:
- These are table of contents entries showing only page number changes; no substantive MD&A content comparison is possible from the provided excerpts
- The source texts provided are limited to section headers and page references, not the full MD&A content
Risk Factors
- Added:
- Added 'objective' to list of forward-looking statement identifiers in newer filing (2026-05-11)
- Added 'global macroeconomic conditions' as standalone bullet point in newer filing (2026-05-11)
- Removed:
- Removed 'our plans regarding, and our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements' bullet point; replaced with simpler version in newer filing (2026-05-11)
- Removed 'the rate and degree of market acceptance and clinical utility of our programs' and changed to 'the rate and degree of market acceptance of our programs' in newer filing (2026-05-11)
- Removed entire bullet point on 'adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), volatility in financial markets and other challenges in the global economy' from older filing (2025-11-10)
- Removed entire bullet point on 'uncertainty around the funding, functioning and policy priorities of the U.S. federal regulatory agencies, including the U.S. Food and Drug Administration' from older filing (2025-11-10)
- Reworded:
- Changed 'our product candidates' to 'our programs' in first bullet point (newer filing 2026-05-11)
- Changed 'and commercialization' to 'and potential commercialization' in second bullet point (newer filing 2026-05-11)
- Changed 'the continuation of our existing collaborations and licensing and other arrangements and entry into new collaborations and licensing and other arrangements that may be necessary or desirable' to simpler phrasing in newer filing (2026-05-11)
- Removed 'and clinical utility' modifier from market acceptance bullet in newer filing (2026-05-11)
- Relocated 'global macroeconomic conditions' from detailed list to standalone simpler bullet in newer filing (2026-05-11)
- Removed 'business trends and' and kept only 'expected markets and business trends' in forward-looking statements introduction (newer filing 2026-05-11)
- Notes:
- The newer filing is incomplete (text cuts off mid-section), limiting ability to assess full Risk Factors section
- Comparison limited to Special Note Regarding Forward-Looking Statements section and opening Risk Factors page numbers
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 12 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($737935) — 1 selling insider
- Last 90 days0 buys · 12 sells ($20M) — 2 selling insiders
- Last 180 days0 buys · 23 sells ($24M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-05. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about APGE's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding APGE as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 16,163,508
- Reported value $1,360,482,386
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
APGE had 4,217,209 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for APGE because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 4,217,209
- Prior settlement (shares) 4,133,296
- Reported change 2.03%
- Days to cover (reported) 4.03
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Sanofi (SNY)
- Regeneron Pharmaceuticals (REGN)
- AstraZeneca (AZN)
- GSK (GSK)
- Eli Lilly (LLY)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare APGE vs…
APOGEE THERAPEUTICS INC is found in…
Frequently asked questions
What does APOGEE THERAPEUTICS INC (APGE) do?
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologic product candidates for the treatment of inflammatory and immunology conditions. Its development programs target high unmet needs in diseases including atopic dermatitis, asthma, eosinophilic esophagitis, and chronic obstructive pulmonary disease. The company is currently a party to a pending acquisition agreement with AbbVie.
What sector is APOGEE THERAPEUTICS INC (APGE) in?
APOGEE THERAPEUTICS INC (APGE) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are APOGEE THERAPEUTICS INC's (APGE) competitors?
Notable peers of APOGEE THERAPEUTICS INC (APGE) include Sanofi, Regeneron Pharmaceuticals, AstraZeneca, GSK and Eli Lilly. This peer set is informational only — not financial advice.
Is APOGEE THERAPEUTICS INC (APGE) overbought or oversold right now?
APOGEE THERAPEUTICS INC (APGE) is currently in overbought territory (its 14-day RSI is 78, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on APGE come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.